BIO Applauds House Committee Vote to Repeal IPAB

  • Contact: Stephanie Fischer
  • Phone: 202-312-9263
  • Email:
  • Recommend
  • Tweet
  • Print
  • Email

Washington, DC (March 6, 2012) – The Biotechnology Industry Organization (BIO) applauded the House Energy and Commerce Committee’s passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law.

“Repealing IPAB is essential to protecting Americans’ access to quality medical care and is particularly important to populations such as seniors who rely on Medicare,” stated BIO President and CEO Jim Greenwood.  “We urge Congress to pass the Medicare Decisions Accountability Act in order to safeguard patient access to life-saving therapies.”

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.